HOPA-ONS Critical Conversations: TIL Webinar Series - On-Demand

Authors:

• Kristin Ferguson, RN, DNP, MBA, OCN
• Kirollos Hanna, PharmD, BCOP, BCPS
• Linda Ramsdell, MSN, FNP-BC, OCN

Course description

Tumor-infiltrating lymphocyte (TIL) therapy is a form of immunotherapy that leverages a patient's immune system to combat cancer. The treatment involves isolating T cells from a patient's tumor, expanding their numbers in a laboratory setting, and reintroducing them into the patient to target and destroy cancer cells. This session will review operational best practices for adopting a TIL therapy program. We will review legal considerations, Information Security, nurse education, hospital administration, pharmacy considerations and therapeutics, stakeholder analysis, and physician leadership considerations utilizing a panel of experts through a moderator-led panel.

Learning Objectives

1. Understand the role of TIL therapy in cancer care
2. Highlight operational best practices for implementation and adoption of TIL therapy
3. Describe the role of the care team in the management of patients on TIL therapy

UAN# 0465-0000-24-131-H01-P

Authors:

• Patricia Chambers, RN, BSN, BMTCN
• Jennifer Collins, PharmD, BCOP
• Andrea Fadel, RN, BSN, BMTCN, OCN
• Amanda Pawlenty, PharmD, BCOP, RPh

Course description

Join us for a panel discussion regarding FDA-approved TIL therapy for melanoma. We will discuss the mechanism of action and toxicities of TIL therapy, LD chemo, and IL-2. Additionally, we'll review logistics for scheduling resections, out of specification products, best practices for safely administering IL2, and where TILs may be in the future.

Learning Objectives

1. Explain the mechanism of action of TIL therapy
2. Summarize the workflow of treating a patient with TIL therapy
3. Compare best practices for safe administration of IL2
4. Identify common barriers to implementing a TILs program

UAN# 0465-0000-24-133-H01-P

Authors:

• Andrea Fadel, RN, BSN, BMTCN, OCN
• Rebecca Gonzalez, PharmD, BCOP
• Eugene Przespolewski, PharmD, BCOP, DPLA
• Lauren Walford, RN, BSN, BMTCN

Course description

Advancements in cancer treatment have led to the first FDA-approved cellular therapy product to treat solid tumors. This tumor-infiltrating lymphocyte (TIL) therapy has been added to the treatment armamentarium for patients with metastatic melanoma at a critical point in their cancer journey. As this exciting treatment option becomes reality, institutions can face many challenges as they attempt to integrate this new therapy into current practices. This panel session will explore the TIL journey from initial evaluation through hospitalization and supportive care. We will discuss common obstacles, logistical considerations, multidisciplinary approaches, and best practices associated with the TIL process.

Learning Objectives

1. Discuss common obstacles and barriers of onboarding patients for tumor-infiltrating lymphocyte (TIL) therapy
2. Evaluate logistical considerations for coordination of care for TIL therapy
3. Illustrate multidisciplinary approaches for maintaining the TIL course
4. Review supportive care measures and best practices post-TIL infusion